Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background: Liver biopsies have been partially replaced by noninvasive methods for assessing liver fibrosis. We explored the usefulness of four novel biomarkers, enhanced liver fibrosis (ELF), glycosylation isomer of Mac-2 binding protein (M2BPGi), galectin-3, and soluble suppression of tumorigenicity 2 (sST2), in association with liver fibrosis. Methods: ELF, M2BPGi, galectin-3, and sST2 were assayed in 173 patients with chronic liver diseases. The results were analyzed according to fibrosis grade (F0/1, F2, and F3/4) by transient elastography (TE). Results: ELF, M2BPGi, galectin-3, and sST2 values differed significantly according to TE grade; ELF and M2BPGi values were higher in F2 and F3/4 than in F0/1 (P ≤0.001, all), sST2 values were higher in F3/4 than in F0/1 and F2 (P <0.05), and galectin-3 values were higher in F3/4 than in F0/1 (P =0.0036). ELF and M2BPGi showed good TE fibrosis detection performance (area under the curves [AUC], 0.841 and 0.833 for ≥F2; and 0.837 and 0.808 for ≥F3). The sensitivity and specificity for predicting TE grade F≥2 were 84.1% and 76.7% for ELF and 63.6% and 91.5% for M2BPGi. Conclusions: This is the first study to compare the liver fibrosis assessment of four novel biomarkers: ELF, M2BPGi, galectin-3, and sST2. The biomarkers varied significantly according to TE grade, and each biomarker showed a different trend. ELF and M2BPGi seem to have comparable good performance for detecting liver fibrosis.
Abstract
Background: Liver biopsies have been partially replaced by noninvasive methods for assessing liver fibrosis. We explored the usefulness of four novel biomarkers, enhanced liver fibrosis (ELF), glycosylation isomer of Mac-2 binding protein (M2BPGi), galectin-3, and soluble suppression of tumorigenicity 2 (sST2), in association with liver fibrosis. Methods: ELF, M2BPGi, galectin-3, and sST2 were assayed in 173 patients with chronic liver diseases. The results were analyzed according to fibrosis grade (F0/1, F2, and F3/4) by transient elastography (TE). Results: ELF, M2BPGi, galectin-3, and sST2 values differed significantly according to TE grade; ELF and M2BPGi values were higher in F2 and F3/4 than in F0/1 (P ≤0.001, all), sST2 values were higher in F3/4 than in F0/1 and F2 (P <0.05), and galectin-3 values were higher in F3/4 than in F0/1 (P =0.0036). ELF and M2BPGi showed good TE fibrosis detection performance (area under the curves [AUC], 0.841 and 0.833 for ≥F2; and 0.837 and 0.808 for ≥F3). The sensitivity and specificity for predicting TE grade F≥2 were 84.1% and 76.7% for ELF and 63.6% and 91.5% for M2BPGi. Conclusions: This is the first study to compare the liver fibrosis assessment of four novel biomarkers: ELF, M2BPGi, galectin-3, and sST2. The biomarkers varied significantly according to TE grade, and each biomarker showed a different trend. ELF and M2BPGi seem to have comparable good performance for detecting liver fibrosis.
참고문헌 (33)
- Friedman SL, "Mechanisms of hepatic fibrogenesis", Gastroenterology, 134, pp.1655~1669 (2008)[DOI]
- Kim JH, "Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment", Liver Int, 35, pp.1103~1115 (2015)[DOI]
- Lok AS, "Hepatitis B: liver fibrosis and hepatocellular carcinoma", Gastroenterol Clin Biol, 33, pp.911~915 (2009)[DOI]
- Dienstag JL, "Lamivudine as initial treatment for chronic hepatitis B in the United States", N Engl J Med, 341, pp.1256~1263 (1999)[DOI]
- Kim SU, "Clinical application of liver stiffness measurement using transient elastography: a surgical perspective", Digestion, 88, pp.258~265 (2013)[DOI]
- Bravo AA, "Liver biopsy", N Engl J Med, 344, pp.495~500 (2001)[DOI]
- Rousselet MC, "Sources of variability in histological scoring of chronic viral hepatitis", Hepatology, 41, pp.257~264 (2005)[DOI]
- Tsochatzis EA, "Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy", J Hepatol, 54, pp.650~659 (2011)[DOI]
- Kim MN, "Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis", Hepatology, 61, pp.1851~1859 (2015)[DOI]
- Friedrich-Rust M, "Critical comparison of elastography methods to assess chronic liver disease", Nat Rev Gastroenterol Hepatol, 13, pp.402~411 (2016)[DOI]
- Castera L, "Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C", J Hepatol, 52, pp.191~198 (2010)[DOI]
- Imbert-Bismut F, "Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study", Lancet, 357, pp.1069~1075 (2001)[DOI]
- Kuno A, "A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis", Sci Rep, 3, pp.1065~ (2013)[DOI]
- Abe M, "Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease", J Gastroenterol, 50, pp.776~784 (2015)[DOI]
- Yamasaki K, "Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients", Hepatology, 60, pp.1563~1570 (2014)[DOI]
- Ito K, "LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients", Hepatology, 56, pp.1448~1456 (2012)[DOI]
- Wettersten N, "Biomarkers for heart failure: an update for practitioners of internal medicine", Am J Med, 129, pp.560~567 (2016)[DOI]
- Yancy CW, "2013 ACCF", AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation, Circulation, pp.2013, 128[DOI]
- Henderson NC, "The regulation of inflammation by galectin-3", Immunol Rev, 230, pp.160~171 (2009)[DOI]
- Hsieh WC, "Galectin-3 regulates hepatic progenitor cell expansion during liver injury", Gut, 64, pp.312~321 (2015)[DOI]
- Mueller T, "The Presage((R)) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2", Expert Rev Mol Diagn, 13, pp.13~30 (2013)[DOI]
- 허미나, "Soluble ST2 Has a Prognostic Role in Patients With Suspected Sepsis", Annals of Laboratory Medicine, 35(6), pp.570~577 (2015), 대한진단검사의학회
- Kim H, "Multimarker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis", Ann Intensive Care, 7, pp.27~ (2017)[DOI]
- Pejnovic N, "Galectin-3 and IL-33", ST2 axis roles and interplay in diet-induced steatohepatitis, 2016, pp.22, 9706~9717
- Kamath PS, "The model for end-stage liver disease (MELD)", Hepatology, 45, pp.797~805 (2007)[DOI]
- Murray KF, "AASLD practice guidelines: evaluation of the patient for liver transplantation", Hepatology, 41, pp.1407~1432 (2005)[DOI]
- Lichtinghagen R, "The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values", J Hepatol, 59, pp.236~242 (2013)[DOI]
- McHugh ML, "Interrater reliability: the kappa statistic", Biochem Med (Zagreb), 22, pp.276~282 (2012)
- Weinstein MC, "Clinical decision analysis" (1980), WB Saunders
- Parkes J, "Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C", J Viral Hepat, 18, pp.23~31 (2011)[DOI]
- Kim BK, "Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B", PLoS One, 7, pp.e41964~ (2012)[DOI]
- "2016", ~
- Tapper EB, "Use of liver imaging and biopsy in clinical practice", N Engl J Med, 377, pp.756~768 (2017)[DOI]